GB695787A - Improvements in anticoagulants - Google Patents

Improvements in anticoagulants

Info

Publication number
GB695787A
GB695787A GB3050949A GB3050949A GB695787A GB 695787 A GB695787 A GB 695787A GB 3050949 A GB3050949 A GB 3050949A GB 3050949 A GB3050949 A GB 3050949A GB 695787 A GB695787 A GB 695787A
Authority
GB
United Kingdom
Prior art keywords
less
ester
salt
sodium
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB3050949A
Inventor
Colin Robert Ricketts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Development Corp UK
Original Assignee
National Research Development Corp UK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Development Corp UK filed Critical National Research Development Corp UK
Priority to GB3050949A priority Critical patent/GB695787A/en
Publication of GB695787A publication Critical patent/GB695787A/en
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention comprises the water-soluble salts of sulphuric esters derived from dextrans of intrinsic viscosity less than 0.04, said esters having 9 per cent or more of sulphur in their sodium salts. The compounds are made by the degradation of high molecular weight dextrans, fractionation of the mixture to remove products whose intrinsic viscosity is 0.04 or more, esterifying the lower fraction with a sulphating agent and converting the ester into a water-soluble salt, e.g. of an alkali or alkaline earth metal. The ester may have up to 3 sulphate groups per glucose unit and its sodium salt preferably has 14 per cent or more sulphur. The molecular weight is less than 22,000. An example is given of the preparation of a suitable ester-salt, using chlorosulphonic acid with pyridine for the esterification and sodium hydroxide for neutralization; the product has 17.15 per cent of sulphur. Specification 603,571 is referred to. According to the Provisional Specification the dextran may be any whose molecular weight is less than 25,000.ALSO:Anticoagulants for use with blood and plasma consist mainly or entirely of a water-soluble salt of dextran sulphate, the latter being the sulphuric ester of a dextran whose intrinsic viscosity is less than 0.04; the ester has a sulphur content of not less than 9 per cent calculated on its sodium salt. The ester may have up to 3 sulphate groups per glucose unit, the molecular weight being less than 22,000. A sterile isotonic solution can be made by autoclaving a solution of the salt together with sodium chloride and a buffer, e.g. sodium bicarbonate. The salt may be of an alkali or alkaline earth metal, especially sodium. A test is described to ensure that the anticoagulants are non-toxic in vivo. Specification 603,571 is referred to. According to the Provisional Specification there may be used any dextran whose molecular weight is less than 25,000.
GB3050949A 1949-11-28 1949-11-28 Improvements in anticoagulants Expired GB695787A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB3050949A GB695787A (en) 1949-11-28 1949-11-28 Improvements in anticoagulants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB3050949A GB695787A (en) 1949-11-28 1949-11-28 Improvements in anticoagulants

Publications (1)

Publication Number Publication Date
GB695787A true GB695787A (en) 1953-08-19

Family

ID=10308795

Family Applications (1)

Application Number Title Priority Date Filing Date
GB3050949A Expired GB695787A (en) 1949-11-28 1949-11-28 Improvements in anticoagulants

Country Status (1)

Country Link
GB (1) GB695787A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0066379A2 (en) * 1981-05-15 1982-12-08 Riker Laboratories, Inc. Composition for combating herpes virus

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0066379A2 (en) * 1981-05-15 1982-12-08 Riker Laboratories, Inc. Composition for combating herpes virus
EP0066379A3 (en) * 1981-05-15 1983-06-08 Riker Laboratories, Inc. Composition for combating herpes virus

Similar Documents

Publication Publication Date Title
KR910008329B1 (en) Process for preparing depolymerized and super sulfated heparin
ES2150589T3 (en) POLYSACCHARIDES WITH A HIGH CONTENT OF IDURONIC ACID.
ES8206555A1 (en) Sulfated polysaccharides, process for their preparation and their use as medicines.
US3454560A (en) Process for the production of chondroitin polysulfate
GB695787A (en) Improvements in anticoagulants
GB603571A (en) Compounds having a retarding action on the coagulation of blood and processes of preparing the same
RU2000100374A (en) MIXTURES OF OLIGOSACCHARIDES, possessing anti-thrombotic activity
Jorpes et al. On the relationship between the sulphur content and the anticoagulant activity of heparin preparations
GB541528A (en) Improvements in or relating to the hydrolysis of pectin
GB715821A (en) Improvements relating to the manufacture of sulphuric esters of dextran
GB573589A (en) Improvements in or relating to the manufacture of alginic materials
Wolfrom et al. A synthetic heparinoid from amylose
CHAYANSUPAP et al. Synthesis and Bioactivities of Pectin Sulfate
GB740152A (en) Sulfate esters of partially degraded chitin and salts thereof
GB704516A (en) A blood anticoagulating agent and process for the manufacture thereof
GB746870A (en) Preparation of sulphated chitosan
GB555842A (en) Improvements in or relating to the production of pectinic acids from sugar beet pulp
GB620733A (en) Improvements in and relating to carbazole derivatives
GB770075A (en) Improvements in or relating to preparation of a fibrinogen product and stable solutions thereof
GB962585A (en) Detergent compositions
GB383611A (en) Manufacture of cellulose ethers
GB480096A (en) Improvements relating to the extraction of pectins
GB420529A (en) Improvements in and relating to the manufacture of cellulose esters
GB370497A (en) Improvements in and relating to the manufacture of artificial mordanting substances
GB700721A (en) Organic acid esters of cellulose